rosuvastatin

rosuvastatin is a potent HMG-CoA reductase inhibitor belonging to the class of medications known as statins. It is primarily prescribed for the management of dyslipidemia to reduce the risk of cardiovascular disease in appropriate patients. The drug is marketed globally under brand names such as Crestor and is a subject of ongoing clinical research within major institutions like the National Institutes of Health.

Medical uses

Rosuvastatin is indicated for the treatment of hypercholesterolemia, including cases of familial hypercholesterolemia, and to slow the progression of atherosclerosis. It is used in both primary and secondary prevention settings to reduce the incidence of major cardiovascular events, such as myocardial infarction and stroke. Guidelines from the American Heart Association and the European Society of Cardiology often reference its use based on outcomes from large trials like JUPITER trial. The medication is also employed in the management of certain dyslipidemia profiles associated with conditions like diabetes mellitus.

Adverse effects

Common adverse reactions include myalgia, headache, and abdominal pain. More serious but rare risks involve rhabdomyolysis, hepatotoxicity, and the development of new-onset diabetes. Post-marketing surveillance by agencies such as the Food and Drug Administration and the European Medicines Agency has noted reports of proteinuria and hematuria. The risk of myopathy is increased with concomitant use of drugs like cyclosporine or gemfibrozil.

Pharmacology

Rosuvastatin functions as a competitive inhibitor of the enzyme HMG-CoA reductase, which is the rate-limiting step in the mevalonate pathway within the liver. This action potently decreases the hepatic synthesis of cholesterol and upregulates the expression of LDL receptors on hepatocytes, leading to increased clearance of low-density lipoprotein from the bloodstream. Its pharmacokinetics are characterized by minimal metabolism via the cytochrome P450 system, specifically CYP2C9, and it is a substrate for transport proteins like OATP1B1.

History

Rosuvastatin was discovered and developed by the pharmaceutical company Shionogi & Co., Ltd. in Japan. It was later codeveloped and licensed for international markets through a collaboration with AstraZeneca. The drug received its first regulatory approval from the Medicines and Healthcare products Regulatory Agency in the United Kingdom in 2002, followed by approval from the Food and Drug Administration in the United States in 2003. The pivotal JUPITER trial, presented at the American Heart Association scientific sessions, significantly influenced its adoption for primary prevention.

Society and culture

Rosuvastatin, under the brand Crestor, became one of the top-selling pharmaceuticals globally, generating significant revenue for AstraZeneca. Its patent expiration in various territories, including rulings by the United States Court of Appeals for the Federal Circuit, led to the introduction of numerous generic drug versions from companies like Teva Pharmaceutical Industries and Mylan. The drug's cost and access have been subjects of discussion within healthcare systems like the National Health Service and among policymakers in Congress.

Category:Drugs